

UNCLASSIFIED

AD NUMBER
ADB274596
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jul 2001. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 26 Aug 2002

THIS PAGE IS UNCLASSIFIED

AD_____

Award Number: DAMD17-98-1-8205

TITLE: The Human Breast Cancer Cell DNA Synthesome Can Serve as
a Novel In Vitro Model System for Studying the Mechanisms
of Action of Anticancer Drugs

PRINCIPAL INVESTIGATOR: Luciana Macedo
Linda Malkas, Ph.D.

CONTRACTING ORGANIZATION: University of Maryland
Baltimore, Maryland 21201

REPORT DATE: July 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Jul 01). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20020124 387

NOTICE


USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8205
Organization: University of Maryland

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.



01/04/02

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2001	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 98 - 30 Jun 01)	
4. TITLE AND SUBTITLE The Human Breast Cancer Cell DNA Synthesome Can Serve as a Novel In Vitro Model System for Studying the Mechanisms of Action of Anticancer Drugs			5. FUNDING NUMBERS DAMD17-98-1-8205	
6. AUTHOR(S) Luciana Macedo Linda Malkas, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Maryland Baltimore, Maryland 21201 E-Mail: lulyfurtad@hotmail.com			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Report contains color.				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) This report describes preliminary results from our studies at the use of breast cancer DNA Synthesome as an <i>In Vitro</i> Model system to evaluate the mechanism of action of anticancer drugs. In this work the pharmacological profile of new eight hydrazone derivatives structurally designed as ribonucleotide reductase inhibitors are discussed. Also a series of new seven 1,4-naphtoquinones derivatives structurally related to the natural product lapachol and designed to act as topoisomerase inhibitors were investigated as well. The antiproliferative activity and the ability to inhibit DNA synthesis through preventing ³ H-thymidine incorporation were determined using MCF-7 breast cancer cell lines and some derivatives showed significant results. Our study showed also that the hydrazone new drugs were unable to inhibit the cellular DNA synthetic apparatus in the <i>in vitro</i> DNA replication assay using the human breast cancer DNA synthesome multi-protein complex what is consistent with their being RR inhibitors since the deoxyribonucleotide biosynthesis enzymes are not a part of the DNA synthesome. At least four compounds of the 1,4-naphtoquinone series showed remarkable results and seem to be promising drugs for the study of the appliance of the breast cancer DNA synthesome as a model system to evaluate anticancer drugs.				
14. SUBJECT TERMS Breast Cancer MCF7, synthesome, DNA replication, cell proliferation, anticancer drugs				15. NUMBER OF PAGES 23
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	
SF 298.....	2
Table of Contents.....	3
Introduction.....	4-5
Body.....	5-17
Key Research Accomplishments.....	17-18
Reportable Outcomes.....	18
Conclusions.....	18-19
References.....	19-22

ABSTRACT

This report describes preliminary results from our studies at the use of breast cancer DNA Synthesome as an *In Vitro* Model system to evaluate the mechanism of action of anticancer drugs. In this work the pharmacological profile of new eight hydrazone derivatives structurally designed as ribonucleotide reductase inhibitors are discussed. Also a series of new seven 1,4-naphthoquinones derivatives structurally related to the natural product lapachol and designed to act as topoisomerase inhibitors were investigated as well. The antiproliferative activity and the ability to inhibit DNA synthesis through preventing ^3H -thymidine incorporation were determined using MCF-7 breast cancer cell lines and some derivatives showed significant results. Our study showed also that the hydrazone new drugs were unable to inhibit the cellular DNA synthetic apparatus in the *in vitro* DNA replication assay using the human breast cancer DNA synthesome multi-protein complex what is consistent with their being RR inhibitors since the deoxyribonucleotide biosynthesis enzymes are not a part of the DNA synthesome. At least four compounds of the 1,4-naphthoquinone series showed remarkable results and seem to be promising drugs for the study of the appliance of the breast cancer DNA synthesome as a model system to evaluate anticancer drugs.

INTRODUCTION

Breast cancer is one of the commonly diagnosed female cancers and the second leading cause of cell death among women (Weinberg, R. A., 1996). Besides that, the treatments traditionally used in the cancer treatment obtained positive results only in a small percentage of solid tumors and resulted in undesired side effects (Alessandro, R. *et al.*, 1996; Hellman, S., Vokes, E. E., 1996). Clarification of the mechanism of action of chemotherapeutic agents at the cellular and molecular levels is crucial to the development of more effective and rational breast cancer treatment and more specific drugs with less toxicity (Weinberg, R. A., 1996; Alessandro, R. *et al.*, 1996; Barinaga, M., 1997; Fearon, E. R., 1997). Our research group was the first to successfully isolate and purify a functional multiprotein DNA replication complex from human breast cancer cells, which was designated the DNA synthesome (Malkas, L. H. *et al.*, 1990; Wu, Y. *et al.*, 1994; Applegren, N. *et al.*, 1995; Simbulan-Rosenthal, C. M. *et al.*, 1996; Coll, J. M. *et al.*, 1996; Lin, S. *et al.*, 1997; Coll, J. M. *et al.*, 1997; Sekowski, J. W. *et al.*, 1998; Sekowski, J. W. *et al.*, 1998; Bechtel, P. E. *et al.*, 1998; Simbulan-Rosenthal, C. M., 1998). The discover and characterization of the DNA synthesome lead us to the development of a new and powerful *in vitro* replication system DNA synthesome-driven. This new model can be used to study the mechanism of action of anticancer drugs which directly affect the DNA synthesis (Wills, P. *et al.*, 1996; Coll, J. M. *et al.*, 1996) and will greatly facilitate the development of improved anti-breast cancer drugs.

As part of a research program aiming at the appliance of the breast cancer DNA synthesome as model system for studying the mechanism of action of anticancer drugs and while searching for new compounds presenting an antiproliferative activity on breast cancer cells we report the preliminary pharmacological evaluation of two new series of antiproliferative compounds.

One of this new series investigated are hydrazones derivatives (Figures 1) compounds LASSBio 466, 467, 431, 276, 273 and 578 (Lima, L. M. *et al.*, 1999; Lima, P. C. *et al.*, 1999; de Souza, A. F. *et al.*, 1998; de Souza, A. F. *et al.*, 1999) (Figure 1), structurally designed to act as ribonucleotide reductase (RR) inhibitors. The sulfonylurea derivatives LASSBio 378 and LASSBio215 (Figure 1) were also evaluated (Figures 2 and 3 and Table 1) in order to investigate the contribution of the sulfonylthiourea and sulfonamide urea units to the antiproliferative activity. The therapeutic benefits of inhibitors of the enzyme ribonucleotide reductase (RR) (Cory, J. G., *et al.*, 1983; Smith, E. L. *et al.*, 1985) have been well established in many neoplastic diseases. A classic example is the antitumor drug hydroxyurea which blocks the DNA replication via the inhibition of the RR activity (Navarra, P., Preziosi, P., 1999). These therapeutic effects are based on the important role played by the RR which catalyzes the conversion of the ribonucleotides into deoxyribonucleotides in the cytoplasm (Engstrom, Y. *et al.*, 1988) and it is considered the rate-limiting step of DNA synthesis and hence cell proliferation (Elford, H. L. *et al.*, 1970; Weber, G., 1977; Cory, J. G., Sato, A., 1983).

We decided also to evaluate a new series of 1,4-naphtoquinones derivatives structurally related to the natural product lapachol. 1,4-naphtoquinones are widespread in nature and have been isolated from plants and exhibit interesting biological activities (Thomson, R. H., 1971; Morton, R. A., 1965). Lapachol (2-hydroxy-3-prenyl-1,4-naphtoquinine), found in species of *Tabebuia*, was shown to be active against Walker-256 carcinoma and Yoshida sarcoma (Driscoll, J. S., *et al.*, 1974; Rao, K. V., *et al.*, 1968). Several synthetic derivatives of lapachol have been prepared and showed to be active in leukemia (da Consolacao, M., *et al.*, 1975), and in a panel of solid tumors *in vitro* (Ueda, S., *et al.*, 1994; Saizarbitoria, T. C., *et al.*, 1992; Kingston, D. G. *et al.*, 1980).

BODY

Investigation on the activity of the hydrazone series in breast cancer cells

Materials

The drugs tested LASSBio 466, 467, 276, 273, 378, 431, 578 and 215 were supplied by Dr Eliezer J. Barreiro, Laboratorio de Avaliacao e Sintese de Substancias Bioativas (LASSBio), University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. These derivatives were synthesized in this laboratory as described previously (Lima, L. M. *et al.*, 1999; Lima, P. C. *et al.*, 1999; Souza, A. F. *et al.*,

1998; Souza, A. F. *et al.*, 1999). The drugs were dissolved in dimethyl sulfoxide (DMSO) and prepared as 1M, 100 mM and 1mM stock solutions and stored at -5°C.

The hydroxyurea and araCTP (Sigma) were dissolved in deionized water and prepared as 1M and 100mM stock solutions and stored at -5°C.

In the assays using MCF-7 cells we used MEM medium (GibcoBRL), 1mM sodium pyruvate (90 %) (GibcoBRL) supplemented with 10% fetal bovine serum, 1 % penicillin/streptomycin (will be referred to as complete medium). The drug solutions diluted with the appropriate medium were sterilized by passing through syringe filter (0.2 µm) (Nalgene). The concentration of DMSO used in the final solutions had no effect on cellular proliferation, [³H]thymidine incorporation in the DNA or *in vitro* SV40 DNA replication observed in the respective assays.

Cell Proliferation Assay

The effect of the test-compounds on MCF-7 cellular proliferation was examined using the MTT colorimetric assay (Mossmann, T., 1983; Denizot, F. & Lang, R., 1986; Barile, F. A., 1994).

The MCF-7 cells were seeded in 96-well flat bottomed dishes (Falcon, Becton Dickinson Lab-ware) at $1.2-3.2 \times 10^4$ cells/mL (100 µL). Twenty four hours later, when the cells were in exponential growth, the test-compounds were added at different concentrations. Each drug concentration was tested in four separate wells and at least five different concentrations of each drug were used to determine the IC₅₀ as a mean of at least two separate experiments.

The cells were incubated for 24, 48, 72 and 96 hours in the absence and presence of the test-compounds. After the incubation period, the medium was removed and replaced with a 1mg/mL (1mL) MTT solution in MEM without bovine fetal serum or antibiotic. The plates were incubated at 37°C for 3 hours.

At the end of the incubation period the untransformed MTT was removed and DMSO was added to each well. The plates were then vigorously shaken for 5 minutes and the absorbance of each well was measured at 560 nm a 96-well plate reader (Victor 1420 Multilabel Counter - Wallac). The absorbance values were corrected for by preparation of blank wells containing all additions apart from the cells. The results were expressed as the means of 4 replicates. The inhibitory concentration value (IC₅₀) was defined as the concentration of drug that reduced absorbance to 50 % of that found for the untreated control 70 hours after adding the compounds. The IC₅₀ was determined mathematically based on the Hill coefficient (Figure1, table 1).

The cytotoxic effect of DMSO was obtained previously at the same assay conditions.

Some structure-activity analysis could be concluded from this experiment. Table 1 and Figure 1 demonstrates that all of the hydrazone analogues inhibited the cell proliferation in some extent. The acylhydrazone derivatives LASSBio 466 and 467 inhibited the MCF-7 cell proliferation (IC₅₀ = 3.5 and 8.9 µM) to a greater

extent than the sulfonyl hydrazone compounds (LASSBio 273, 276 and 578) in the same experiments ($IC_{50} = 121.4, 145.4$ and $\geq 300 \mu M$). The acylhydrazone compound LASSBio 431 ($IC_{50} = 283.9 \mu M$) which doesn't have the OH aromatic substituent, as expected, showed less activity than the analogues 466 and 467. Curiously, LASSBio273, which can coordinate with intracellular iron only in a bidentate manner, showed a compared activity with LASSBio276 in this assay. On the other hand, the results obtained with the compound LASSBio578 showed that the introduction of a hydroxylic substituent in the 2 position of the aromatic ring leading to the formation of a $OH^*-N^*-O^*$ tridentate ligand system resulted in a loss of activity when compared with the analogs LASSBio 273 and 276.

These results confirm that similar to the compounds pyridoxal isonicotinoyl hydrazones (Richardson, D. R., Milnes, K., 1997) and thiosemicarbazones (Antonini, I. *et al.*, 1981) the presence of a tridentate ligand system $X^*-N^*-Y^*$ is important for the antiproliferative activity as also for the RR inhibition at least in the acylhydrazone series. The small difference between the IC_{50} data obtained for LASSBio466 and LASSBio467 for the cell lines tested indicates that probably there is no conformational effects interfering in the coordination geometry of this series of compounds.

In order to investigate the possible pharmacophoric contribution of the acylhydrazone moiety of LASSBio 466 and 467 and the structural related sulfonylhydrazone bioisoster moiety of LASSBio 276, 273 and 578, the sulfonamide urea compound LASSBio 378 was also screened against human breast cancer MCF-7 cells in culture as shown in Table 1 and Figure 1. The compound LASSBio 378 showed a reduced activity ($IC_{50} > 300 \mu M$) indicating that the replacement of the sulfonylhydrazone subunit of LASSBio 273 and 276 by the sulfonylthiourea moiety lead to a loss of activity.

Table 1: Inhibition of cell growth and 3H -thymidine incorporation into DNA by several hydrazone analogues.

Compounds	IC ₅₀ (μM)	
	MCF-7 cell proliferation ^a	[3H]thymidine incorporation MCF-7 ^a
Hydroxyurea	nd ^b	319.3 $\pm$ 39.35
LASSBio466	3.52 $\pm$ 0.23	3.55 $\pm$ 0.92
LASSBio467	8.96 $\pm$ 0.63	8.14 $\pm$ 1.81
LASSBio431	283.9 $\pm$ 16.83	130.6 $\pm$ 9.12
LASSBio 276	145.4 $\pm$ 36.87	68.75 $\pm$ 2.74
LASSBio273	121.4 $\pm$ 13.42	58.86 $\pm$ 5.17
LASSBio578	≥ 300	126.5 $\pm$ 3.17
LASSBio378	> 300	147.9 $\pm$ 19.28
LASSBio215	> 300	251.1 $\pm$ 32.64

^a Mean of at least two independent experiments which four replicates determinations were taken within each experiment $\pm$ standard error. ^b nd= not determined.




Figure 1: Effect of the hydrazone derivatives on intact MCF-7 cells proliferation after 70 hours of treatment with the drugs. Each point represents the average of at least two independent experiments in which four replicates determinations were taken; error bars represent the standard errors of the means. Cells grown in the absence of drug served as the controls (100 %) to which the drug-treated cells were compared. The IC_{50} curves were determined mathematically based on the Hill coefficient.

[methyl- ^3H]thymidine incorporation assay

The synthesis of DNA was measured indirectly by measuring [methyl- ^3H]thymidine incorporation. The effects of the compounds were examined by seeding MCF-7 cells in 24-well plates (Falcon, Becton Dickinson Lab-ware) at 1.0×10^4 cells/well in 1 mL of MEM complete medium. The cells were incubated at 37°C , 5% CO_2 and 95 % air for around 24 hours and then 1 mL of complete medium containing the test-compounds at a range of concentrations were added. Each concentration of drug was tested in four separate wells, in at least five concentrations of each drug and in two separated experiments. The inhibitory concentration value (IC_{50}) was defined as the concentration of drug that reduced

tritium incorporation to 50 % of that found for the untreated control 70 hours after adding the compounds. The IC_{50} value was determined mathematically based on the Hill coefficient and is showed in Figure 2 and Table 1.

The cells were incubated for 24, 48, 72 hours after the addition of the drugs. At the end of the period of incubation the cells were labeled with [methyl- 3H]-thymidine (1mCi/mL) (New England Nuclear, Boston, MA) at 1 μ Ci/well for 1 hour at 37 °C. Then the cells were assayed for incorporation of tritium into trichloroacetic acid precipitable material deposited onto GF/C glass fiber filters (25 mm) (Whatman) held in vacuum manifold. The filters were washed with 10 % trichloroacetic acid and 95% ethanol and placed into scintillation vials. Three mL of scintillation fluid Bio-Safe NA (Research Products International Corp., Illinois) was added and the radioactivity per vial was counted on a scintillation counter (Liquid Scintillation Analyzer, Tri-Carb, Packard).

The profile of inhibition obtained in the antiproliferative assay was confirmed in the radioactive assay where the acylhydrazone derivatives LASSBio 466 and 467 were the more potent compounds (IC_{50} = 3.5 and 8.1 μ M) (Table 1, Figure 2) followed by the sulfonylhydrazone derivatives LASSBio 276 and 273 (IC_{50} = 68.75 and 58.86 μ M). The hydrazone compounds showed greater activity when compared to the RR inhibitor hydroxyurea (IC_{50} > 300 μ M). The compounds, which had the hydrazone subunit, replaced by a sulfonylthiourea moiety (LASSBio378) or a sulfonamide urea moiety (LASSBio215) showed a loss of activity as showed in Table 1 and Figure 2.




Figure 2: Effect of the hydrazones analogues and hydroxyurea on intact MCF-7 cell DNA synthesis after 70 hours of treatment with the drugs. Each point represents the average of at least two independent experiments in which four replicates determinations were taken; error bars represent the standard errors of the means. Cells grown and labeled in the absence of drug served as the controls (100 %) to which the drug-treated cells were compared. The IC_{50} curves were determined mathematically based on the Hill coefficient.

Isolation of the MDA-MB486 DNA synthesome

MDA-MB486 (7.4 g) cells were homogenized, and the breast cell DNA synthesome was purified according to our previously published procedure (Coll, J. M. *et al.*, 1996). Briefly, the respective cell pellet was resuspended in one volume of buffer (200mM sucrose, 50 mM HEPES (pH 7.5), 5 mM KCl, 5 mM MgCl, 2 mM DTT, 0.1 mM PMSF) and homogenized using a Dounce homogenizer. The homogenate was then fractionated into a nuclear pellet and a cytosolic extract. The nuclei was extracted with a high salt buffer (2M KCl), while the cytosolic fraction was used to prepare a postmicrosomal supernatant (S-3). The nuclear extract and the postmicrosomal supernatant were combined and

adjusted to 2 M KCl and 5 % polyethylene glycol. The mixture was rocked for 1 h at 4 °C, then centrifuged at 5,000 rpm for 15 min (4 °C). The resulting supernatant was then dialyzed against a buffer containing 0.25 M sucrose. The dialyzed fraction was clarified by centrifugation at 15,000 rpm for 15 min, and the supernatant solution was layered onto a 4 mL 2 M sucrose cushion containing the dialyzes buffer. After centrifugation at 40,000 rpm overnight (4 °C) the supernatant S-4 and sucrose interface P-4 fractions were collected and dialyzed against Kenny's buffer (50 mM Hepes, pH7.5, 5 mM KCl, 10 % glycerol) containing 1 mM DTT. The fractions were then immediately tested for *in vitro* SV40 DNA replication activities.

In vitro SV40 replication assay

The assay was performed essentially as described previously (Malkas, H. *et al.*, 1990) in the absence and presence of different concentrations of drug. Assay reaction mixtures (12.5 µL) contained 30 mM HEPES (pH 7.5); 7.5mM MgCl₂ ; 0.5 mM DTT, purified SV40 large T-antigen, 24.8 ng plasmid pSVO⁺ containing an insert of SV40 replication-origin DNA sequences; 100 µM each dTTP, dATP, dGTP; 200 µM each rCTP, rGTP, UTP; 4mM ATP; 25 µM [α -³²P]dCTP; 40 mM creatine phosphate; 1 µg creatine kinase. Each reaction was incubated for 4 h at 37 °C. The replication assay reaction products were processed using DE81 (Whatman, Maidstone, UK) filter binding to quantitate the amount of radiolabel incorporated into the replication products. The results are showed in Figure 3.

Our results showed that most of these new drugs were unable to inhibit the cellular DNA synthetic apparatus at concentrations up to 300 µM as shown in Figure 3. This is consistent with their being RR inhibitors since the deoxyribonucleotide biosynthesis enzymes are not a part of the DNA synthesesome.

In order to investigate the mechanism of action of this new drugs we had begun to develop RR purification and assay to test this compounds.




Figure 3: Effect of the hydrazone derivatives, hydroxyurea and araCTP on DNA synthesis-mediated *in vitro* SV40 DNA replication. The assays were performed as described above. Each point represents at least two independent experiments in which four replicates determinations were taken; error bars represent the standard errors of the means. Control reactions were performed in the absence of drug (100 %).

** P < 0.001 compared to appropriate control (ANOVA followed by Dunnett test).

Investigation on the activity of the 1,4-naphthoquinone series in breast cancer cells

The drugs tested PCALC8, 12, 13, 17, 22, 23 and 32 were supplied by Dr Paulo R. R. Costa, Laboratorio de Quimica Bioorganica (LBQ), NPPN, University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil. These derivatives were synthesized in this laboratory. The drugs were dissolved in dimethyl sulfoxide (DMSO) and prepared as 1M, 100 mM and 1mM stock solutions and stored at -5°C.

Cell Proliferation Assay

The effect of the test-compounds on MCF-7 cell proliferation was examined using the MTT colorimetric assay (Mossmann, T., 1983; Denizot, F. & Lang, R., 1986; Barile, F. A., 1994).

The MCF-7 cells were seeded in 96-well flat bottom dishes (Falcon, Becton Dickinson Lab-ware) at 1.4×10^5 cells/mL (100 μ L) on day zero. Twenty four hours later, when the cells were in exponential growth, several concentrations of the test-compounds were added.

The cells were incubated for 24 and 48 hours in the absence and presence of the test-compounds and submitted to the same procedures described above. The inhibitory concentration value (IC_{50}) was defined as the concentration of drug that reduced absorbance to 50 % of that found for the untreated control 24 hours after adding the compounds. Each drug concentration was tested in four separate wells and at least five different concentrations of each drug were used to determine the IC_{50} . The IC_{50} values were determined for each drug as a mean of at least three separate experiments and mathematically based on the Hill coefficient (Figure 4, Table 2).

The results indicated that the compounds PCALC23 and PCALC12 have comparable and significant activity and are the most potent antiproliferative inhibitors in this serie (Table 2, Figure 4). About 5.34 μ M of PCALC23 and 7.77 μ M of PCALC12 were required to reduce MCF-7 cell proliferation to 50 % of the control activity measured in the absence of drug in only 24 hours of treatment of the cells. The MCF-7 cells were also inhibited by compounds PCALC22 and PCALC8 but they were less effective at inhibiting cell proliferation than compounds PCALC23 and PCALC12. The IC_{50} values for PCALC22 and PCALC8 in this assay were 27.7 and 29.04 μ M, respectively. The other compounds studied in these serie were also able to inhibit cell growth in a concentration-dependent manner but much less efficiently. Unfortunately, their effect in higher concentrations could not be studied due to their poor solubility in DMSO and aqueous solutions.

Table 2: Inhibition of cell growth and ^3H -thymidine incorporation into DNA by several 1,4-naphthoquinones compounds.

Compounds PCALC	IC ₅₀ (μM) MCF-7 cell proliferation ^a	[^3H]thymidine incorporation MCF-7 ^b
22	27.7 $\pm$ 3.44	3.25 $\pm$ 1.28
13	> 100	nd ^c
17	> 100	nd
8	29.04 $\pm$ 1.23	5.23 $\pm$ 0.95
23	5.34 $\pm$ 0.71	12.86 $\pm$ 2.47
12	7.77 $\pm$ 0.64	3.89 $\pm$ 0.73
32	115.3 $\pm$ 20.54	nd

^a Mean of at least three independent experiments which four replicates determinations were taken within each experiment $\pm$ standard error. ^b Mean of at least one independent experiments which four replicates determinations were taken within each experiment $\pm$ standard error. ^c nd= not determined.




Figure 4: Effect of the 1,4-naphthoquinones derivatives on intact MCF-7 cells proliferation after 24 hours of treatment with the drugs. Each point represents the average of at least three independent experiments in which four replicates determinations were taken; error bars represent the standard errors of the means. Cells grown in the absence of drug served as the controls (100 %) to which the drug-treated cells were compared. The IC_{50} curves were determined mathematically based on the Hill coefficient.

[methyl- 3H]thymidine incorporation assay

The synthesis of DNA was measured as described above. The cells were incubated for 24 and 48 hours after the addition of the drugs. Each concentration of drug was tested in four separate wells, in five concentrations of each drug and in at least one experiment. The inhibitory concentration value (IC_{50}) was defined as the concentration of drug that reduced tritium incorporation to 50 % of that

found for the untreated control 24 hours after adding the compounds. The IC_{50} value was determined mathematically based on the Hill coefficient and is showed in Figure 5 and Table 2.

The effect of the 1,4-naphtoquinones derivatives on 3H -thymidine incorporation into MCF-7 cells was examined to obtain further information on the possible mechanism of action of this compounds. In this assay the IC_{50} of only the most active compounds in the proliferation assay were determined, i. e., PCACL 22, 8, 23 and 12 (Table 2, Figure 5). Most of the compounds tested showed a significant DNA synthesis inhibition with IC_{50} values smaller than 6 μM after 24 hours of cell treatment with the drugs. PCALC 23 was the less active compound in this assay ($IC_{50} = 12.86 \mu M$) (Table, Figure 5). The IC_{50} value in the tritium incorporation assay for PCALC 23 was different from the IC_{50} value obtained in the proliferation experiment, however this drug was tested just once and replicates of this assay must be done with this compound to confirm this first results. The analysis of the data obtained with the compounds PCALC 22 and 8 which had IC_{50} values of 3.25 and 5.23 μM in the 3H -thymidine incorporation assay, respectively, showed that a lower concentration of this two drugs were necessary to inhibit DNA synthesis when compared to the proliferation assay. Further studies on these series of compounds are underway aiming the investigation of their mechanism of action. This future experiments consist of the SV40 DNA synthessome replication assay and effect of this compounds on the DNA synthesome associated DNA polymerase α , topoisomerase I and II.




Figure 5: Effect of the 1,4-naphthoquinones derivatives on intact MCF-7 cell DNA synthesis after 24 hours of treatment with the drugs. Each point represents the average of at least one independent experiment in which four replicates determinations were taken; error bars represent the standard errors of the means. Cells grown and labeled in the absence of drug served as the controls (100 %) to which the drug treated cells were compared. The IC_{50} curves were determined mathematically based on the Hill coefficient.

KEY RESEARCH ACCOMPLISHMENTS

- investigated the antiproliferative activity of a new hydrazone series of compounds in breast cancer cells.

- investigated the antiproliferative activity of a new 1,4- naphtoquinone series of compounds in breast cancer cells.
- investigated the DNA synthesis inhibition activity of a new hydrazone series of compounds in breast cancer cells.
- investigated the DNA synthesis inhibition activity of a new 1,4-naphtoquinone series of compounds in breast cancer cells.
- performed experiment to verify if the human breast cancer DNA synthesome can serve as an *in vitro* model system for studying the mechanism of action of ribonucleotide reductase inhibitors.

REPORTABLE OUTCOMES

Abstracts

Macedo, L. F., Barreiro E. J., Malkas L. H., Albuquerque E. X., Hickey, R. (2000): Antiproliferative Activity of a New Series of Hydrazones Derivatives. Scientific Proceeding of the 91st Annual Meeting of the American Association for Cancer Research. 4157.

Macedo, L. F., Abdel-Aziz, W., Barreiro, E. J., Malkas, L. H., Hickey, R. (2001): Investigations on the Mechanism of Action of Novel Acyl-hydrazones and Sulfonylhydrazones Derivatives. Scientific Proceeding of the 92nd Annual Meeting of the American Association for Cancer Research. 431.

Papers

Da Silva, A. J. M., Buarque, C. D., Brito, F. V., Aurelian, L., Macedo, L. F., Malkas, L., Hickey, R., de Souza, D. V., Nozł, F., Murakami, Y. L. B., Silva, N. M. V., Melo, P. A., Caruso, R. R. B., Castro, N. G., Costa, P. R. R. (2001): Synthesis and preliminary Pharmacological Evaluation of New 1,4-Naphtoquinones Structurally Related to Lapachol. Manuscript in preparation.

Macedo, L. F., Barreiro, E. J., Malkas, L., Hickey, R. (2001): Antiproliferative properties and synthesis of a new series of hydrazone analogues. Manuscript in preparation.

CONCLUSIONS

- The hydrazones compounds LASSBio 466, 467, 276 and 273 inhibited cell proliferation and DNA synthesis in a significative manner being more potent than the RR inhibitor hydroxyurea.

- Analysis of the structure-activity relationships in the hydrazone series suggested some structure features that are responsible for the antiproliferative and DNA synthesis inhibition activity and can be used to design new other drugs with improved efficacy.
- Most of the new hydrazone drugs tested were unable to inhibit the cellular DNA synthetic apparatus (i. e., DNA synthesome) at concentrations up to 300 μ M (LASSBio 273 at 300 μ M showed a light inhibition) which is consistent with them being RR inhibitors since the deoxyribonucleotide biosynthesis enzymes are not a part of the DNA synthesome. The data obtained with araCTP in this assay confirmed results described previously (Abdel-Aziz, W. *et al.*, 2000).
- Our data suggested that at least two of the hydrazone derivatives, LASSBio 466 and 467, may be substantially more effective than hydroxyurea in current treatment protocols.
- The preliminary data obtained with the 1,4-naphthoquinones derivatives are in agreement with them being topoisomerase inhibitors.
- The 1,4-naphthoquinone compounds PCALC 8, 12, 22 and 23 inhibited cell proliferation and DNA synthesis in a very significant manner.

REFERENCES

- ABDEL-AZIZ, W. *et al.* (2000) *Cancer Chemother Pharmacol*, 45, p. 312-319.
- ALESSANDRO, R. *et al.* Signal Transduction As a Therapeutic Target. (1996): *Curr. Top. Microbiol. Immunol.*, 213: 167-188.
- ANTONINI, I. *et al.* (1981) "N*-N*-S* Tridentate Ligand System as Potential Antitumor Agents. *J. Med. Chem.*, 24: 1181-1184.
- APPLEGREN, N. *et al.* (1995) Further Characterisation of the Human Cell Multiprotein DNA Replication Complex.: *J. Cel. Biochem.*, 59: 91-107.
- BARILE, F. A. *In Vitro Cytotoxicology*, CRC Press, Florida, USA, 1994.
- BARINAGA, M. From Bench Top to Bedside. More Than 2 Decades of Research On Oncogenes and Tumor Supressors May Finally Pay Off In a New Generation of More Specific, Less Toxic, Cancer Drugs. *Science*, 278:1036-1039.
- BECHTEL, P. E. *et al.* (1998) A Unique Form of Proliferating Cell Nuclear Antigen Is Present in Malignant Breast Cells. *Câncer Research*, 58: 3264-3269.
- COLL, J. M. *et al.* (1996) The Humman Cell Multiprotein DNA Replication Complex (MRC): The Effect of Camptothecin On Its Ability to Support In Vitro DNA Synthesis. *Câncer Chemother. Pharmacol.*, 39: 97-102.

COLL, J. M. *et al.* (1997) Mapping Specific Protein-Protein Interactions Within the Core Component of the Breast Cell DNA Synthesome. *Oncology Research*, 9: 629-639.

DA CONSOLACAO, M.; LINARDI, F.; DE OLIVEIRA, M. M.; SAMPAIO, M. R. (1975) *J Med Chem*, 18:1159

DE SOUZA, A. F. *et al.* (1998) Síntese Diastereosseletiva de Novos derivados Hidrazônicos, Planejados como Novos Protótipos de Agentes Anti-inflamatórios Resumos 21a Reunião Anual da SBQ, QO-009.

DE SOUZA, A. F. *et al.* (1998) Síntese Diastereosseletiva de Novos derivados Hidrazônicos, Planejados como Novos Protótipos de Agentes Anti-inflamatórios Resumos 21a Reunião Anual da SBQ, QO-009.

DE SOUZA, A. F. *et al.* (1999) Planejamento e Síntese de Novos Padrões Estruturais de Derivados N-Acildrazônicos, Propostos como Novos Candidatos a Agentes Anti-inflamatórios Resumos 22a Reunião Anual da SBQ, 2, MD-131.

DE SOUZA, A. F. *et al.* (1999) Planejamento e Síntese de Novos Padrões Estruturais de Derivados N-Acildrazônicos, Propostos como Novos Candidatos a Agentes Anti-inflamatórios Resumos 22a Reunião Anual da SBQ, 2, MD-131.

DENIZOT, F., LANG, R. (1986) Rapid Colorimetric Assay for Cell Growth and Survival. *Journal of Immunological Methods*, 89: 271-277.

DRISCOLL, J. S.; HAZARD, G. F. J.; WOOD, H. B. J.; GOLDIN, A. (1974) *Cancer Chemother Rep* 2 4: 1.

ELFORD, H. L. *et al.* (1970) Ribonucleotide Reductase and Cell Proliferation. *J. Biol. Chem.*, 245: 5228-5233.

ENGSTROM, Y., ROZELL, (1998) *B. The EMBO Journal*, 7: 1615-1620.

FEARON, E. R. (1997) Human Cancer Syndromes: Clues to the Origin and Nature of Cancer. *Science*, 278: 1043-1050.

HELLMAN, S. & VOKES, E. E. (1996) Advancing Current Treatments for Cancer. *Scientific American*, 275: 84-89.

KINGSTON, D. G.; RAO, M. M.. (1980) *Planta Med* 39[3]: 230,.

LIMA, L. M. *et al.* (1999) New Antithrombotic Aryl-semicarbazide Derivative Synthesized from Natural Safole *J. Braz. Chem. Soc.*, 10, 000.

LIN, S. HICKEY, R. J. & MALKAS, L. H. (1997) The Isolation of a DNA Synthesome From Human Leukemia Cells. *Leukemia Res.*, 21 (6): 501-512.

MALKAS, L. H. *et al.* (1990) A 21S Enzyme Complex from HeLa Cells That Functions in Simian Virus 40 DNA Replication in Vitro. *Biochemistry*, 29, p. 6362-6374.

MORTON, R. A. *Biochemistry of Quinones*; Academic Press: London, 1965.

MOSMANN, T. (1983) Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. *Journal of Immunological Methods*, 65, p. 55-63,.

NAVARRA, P., PREZIOSI, P. (1999) Hydroxyurea: New Insights on an Old Drug. *Critical Reviews in Oncology/Hematology*, 29: 249-255.
of Pharmacognosy , P-12, 1992.

RAO, K. V.; MCBRIDE, T. J.; OLESON, J. (1968) *J. Cancer Res* 28: 1952.

RICHARDSON, D. R. & MILNES, K. (1997) The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents II: The Mechanism of Action of Ligands Derived From Salicylaldehyde Benzoyl Hydrazone and 2-Hydroxy-1-Naphthylaldehyde Benzoyl Hydrazone. *Blood*, 89 (8): 3025-3038.

SAIZARBITORIA, T. C.; ANDERSON, J. E.; MCLAUGHLIN, J. L. COSTA. (1992)
Abstracts Society Abstracts Society of Pharmacognosy , P-12.

SEKOWSKI, J. W. *et al.* (1998) Human Breast Cancer Cells Contain an Error-prone DNA Replication Apparatus. *Cancer Research*, 58: 3259-3263.

SIMBULAN-ROSENTHAL, C. M. *et al.* (1996) The Expression of Poly(ADP-ribose) Polymerase During Differentiation-Linked DNA Replication That Is a Component of the Multiprotein DNA Replication Complex. *Biochemistry*, 36: 11622-11633.

SIMBULAN-ROSENTHAL, C. M. *et al.* (1998) Regulation of the Expression or recruitment of Components of the DNA Synthesome by Poly(ADP-Ribose) Polymerase. *Biochemistry*, 37: 9363-9370.

THOMSON, R. H. Naturally Occurring Quinones; Academic Press: London, 1971.

UEDA, S.; UMEMURA, T.; DOHGUCHI, K.; MATSUZAKI, T.; TOKUDA, H.;
NISHINO, H.; IWASHIMA, A. (1994), *Phytochemistry* 36: 323.

WEBER, G. (1977) *Enzymology of Cancer Cells*. *New Engl. J. Med.*, 296: 486-493.

WEINBERG, R. A. (1996) How Cancer Arises. An Explosion of Research Is Uncovering The Long-Hidden Molecular Underpinnings of Cancer- and Suggesting New Therapies. *Scientific American*, 275: p. 32-40.

WILLS, P. *et al.* (1996) A Novel in vitro Model System for Studying the Action of Ara-C. *Cancer Chemother. Pharmacol*, 38: 366-372.

WU, Y. *et al.* (1994) A 17S Multiprotein Form of Murine Cell DNA Polymerase Mediates Polyomavirus DNA Replication In Vitro. *J. Cel. Biochem.*, 54: 32-46



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Aug 02

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB274369	ADB274596
ADB256383	ADB258952
ADB264003	ADB265976
ADB274462	ADB274350
ADB266221	ADB274346
ADB274470	ADB257408
ADB266221	ADB274474
ADB274464	ADB260285
ADB259044	ADB274568
ADB258808	ADB266076
ADB266026	ADB274441
ADB274658	ADB253499
ADB258831	ADB274406
ADB266077	ADB262090
ADB274348	ADB261103
ADB274273	ADB274372
ADB258193	
ADB274516	
ADB259018	
ADB231912	
ADB244626	
ADB256677	
ADB229447	
ADB240218	
ADB258619	
ADB259398	
ADB275140	
ADB240473	
ADB254579	
ADB277040	
ADB249647	
ADB275184	
ADB259035	
ADB244774	
ADB258195	
ADB244675	
ADB257208	
ADB267108	
ADB244889	
ADB257384	
ADB270660	
ADB274493	
ADB261527	
ADB274286	
ADB274269	
ADB274592	
ADB274604	